Cases & Deals

  • Home
  • Practices
  • Chiesi acquires three hospital products from The Medicines Company

Share

Chiesi acquires three hospital products from The Medicines Company

June 2016

Client(s) Chiesi Farmaceutici S.p.A.

Jones Day advised Chiesi Farmaceutici S.p.A., a pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, in its acquisition of three cardiovascular products -- Kengreal® (cangrelor), Cleviprex® (clevidipine), and rights to Argatroban® for Injection –- from The Medicines Company. The Medicines Company received approximately $262 million in cash at closing, and is entitled to receive up to $480 million in sales-based milestone and royalty payment obligations.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.